AR002005A1 - FRAGMENTS OF MONOCLONAL ANTIBODIES THAT HAVE IMMUNE SUPPRESSIVE ACTIVITY, PROCEDURE FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND METHOD FOR THE SUPPRESSION OF THE IMMUNE RESPONSE. - Google Patents

FRAGMENTS OF MONOCLONAL ANTIBODIES THAT HAVE IMMUNE SUPPRESSIVE ACTIVITY, PROCEDURE FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND METHOD FOR THE SUPPRESSION OF THE IMMUNE RESPONSE.

Info

Publication number
AR002005A1
AR002005A1 ARP950100448A AR10044895A AR002005A1 AR 002005 A1 AR002005 A1 AR 002005A1 AR P950100448 A ARP950100448 A AR P950100448A AR 10044895 A AR10044895 A AR 10044895A AR 002005 A1 AR002005 A1 AR 002005A1
Authority
AR
Argentina
Prior art keywords
fragments
suppression
procedure
preparation
pharmaceutical composition
Prior art date
Application number
ARP950100448A
Other languages
Spanish (es)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR002005A1 publication Critical patent/AR002005A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención consta de fragmento mAb monovalentes (Fab) de mAb que tienen la capacidad de reducir la sensibilidad de la expresión del HLA-DR en célulaspresentadoras del antígeno. Los fragmentos Fab pueden reducir la sensibilidad de dicha expresión del HLA-DR sin la citotoxicidad del mAb madre o de losfragmentos bivalentes (F(ab)2) del mAb. Los fragmentos Fab de la invención son por lo tanto potentes compuestos inmunosupresores específicos para el MHC declase II, sin efectos citotóxicos colaterales.The invention consists of monovalent mAb (Fab) fragments of mAbs that have the ability to reduce the sensitivity of HLA-DR expression in antigen-presenting cells. Fab fragments can reduce the sensitivity of such HLA-DR expression without the cytotoxicity of the parent mAb or the bivalent (F (ab) 2) fragments of the mAb. The Fab fragments of the invention are therefore potent immunosuppressive compounds specific for MHC declase II, with no side cytotoxic effects.

ARP950100448A 1994-12-07 1995-12-05 FRAGMENTS OF MONOCLONAL ANTIBODIES THAT HAVE IMMUNE SUPPRESSIVE ACTIVITY, PROCEDURE FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND METHOD FOR THE SUPPRESSION OF THE IMMUNE RESPONSE. AR002005A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35091594A 1994-12-07 1994-12-07

Publications (1)

Publication Number Publication Date
AR002005A1 true AR002005A1 (en) 1998-01-07

Family

ID=23378740

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP950100448A AR002005A1 (en) 1994-12-07 1995-12-05 FRAGMENTS OF MONOCLONAL ANTIBODIES THAT HAVE IMMUNE SUPPRESSIVE ACTIVITY, PROCEDURE FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND METHOD FOR THE SUPPRESSION OF THE IMMUNE RESPONSE.

Country Status (19)

Country Link
EP (1) EP0787151A1 (en)
JP (1) JP2001506122A (en)
CN (1) CN1168679A (en)
AR (1) AR002005A1 (en)
AU (1) AU4256096A (en)
BR (1) BR9509902A (en)
CA (1) CA2206471A1 (en)
CO (1) CO4480041A1 (en)
CZ (1) CZ172497A3 (en)
FI (1) FI972430A (en)
HU (1) HUT77342A (en)
IL (1) IL116228A0 (en)
MA (1) MA23739A1 (en)
NO (1) NO972522L (en)
PE (1) PE52996A1 (en)
PL (1) PL320610A1 (en)
TR (1) TR199501542A2 (en)
WO (1) WO1996017874A1 (en)
ZA (1) ZA9510195B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0893507A1 (en) * 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
AU5588099A (en) 1998-08-28 2000-03-21 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
EP1156062A1 (en) * 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
ATE365749T1 (en) * 2000-05-12 2007-07-15 Gpc Biotech Ag HUMAN PEPTIDES/PROTEINS THAT CAUSE OR EFFECT THE KILLING OF CELLS, INCLUDING LYMPHOID TUMOR CELLS
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
WO2003048301A2 (en) 2001-10-11 2003-06-12 Protein Design Labs Inc. Anti-hla-dr antibodies and the methods of using thereof
US7262278B2 (en) 2001-10-15 2007-08-28 Kirin Beer Kabushiki Kaisha Anti-HLA-DR antibody
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
CA2794499A1 (en) * 2010-04-01 2011-10-06 Immumomedics, Inc. Antibody-based depletion of antigen-presenting cells and dendritic cells
KR102647825B1 (en) * 2021-07-22 2024-03-14 서울대학교산학협력단 Anti-HLA-DP monoclonal antibody and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068790B1 (en) * 1981-06-25 1986-02-26 The Board Of Trustees Of The Leland Stanford Junior University Allele specific immunotherapeutic method and dosage form
CA2070182C (en) * 1989-12-27 2002-12-24 John Ghrayeb Chimeric immunoglobulin for cd4 receptors
DE69233628T2 (en) * 1991-07-25 2007-04-26 Biogen Idec Inc., San Diego Recombinant antibodies for human therapy

Also Published As

Publication number Publication date
AU4256096A (en) 1996-06-26
BR9509902A (en) 1997-10-21
JP2001506122A (en) 2001-05-15
FI972430A0 (en) 1997-06-06
PL320610A1 (en) 1997-10-13
NO972522D0 (en) 1997-06-03
HUT77342A (en) 1998-03-30
ZA9510195B (en) 1996-06-07
FI972430A (en) 1997-06-06
TR199501542A2 (en) 1996-07-21
NO972522L (en) 1997-08-06
IL116228A0 (en) 1996-03-31
CN1168679A (en) 1997-12-24
CZ172497A3 (en) 1997-10-15
MX9704225A (en) 1997-09-30
EP0787151A1 (en) 1997-08-06
CO4480041A1 (en) 1997-07-09
CA2206471A1 (en) 1996-06-13
WO1996017874A1 (en) 1996-06-13
MA23739A1 (en) 1996-07-01
PE52996A1 (en) 1996-12-12

Similar Documents

Publication Publication Date Title
MX9400166A (en) VEGETABLE PROTEIN MICROSPHERES, HYDROLYZED, MODIFIED AND METHODS FOR THEIR PREPARATION AND USE.
GB2301366A (en) Antibodies against E-selectin
NO20081124L (en) Anti-CD 3 antibody formulations
WO1998057994A3 (en) Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
DK0578774T3 (en) Monoclonal antibodies against stem cell factor receptors
AR010752A1 (en) COMPOUNDS WHICH BIND TO AND ACTIVATE A THROMBOPOYETINE RECEPTOR; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, THEIR USE FOR THE PREPARATION OF MEDICINES, AND PROCESS TO PREPARE SUCH COMPOSITION.
AR002005A1 (en) FRAGMENTS OF MONOCLONAL ANTIBODIES THAT HAVE IMMUNE SUPPRESSIVE ACTIVITY, PROCEDURE FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND METHOD FOR THE SUPPRESSION OF THE IMMUNE RESPONSE.
GR3026219T3 (en) Mouse monoclonal antibodies
NO943967L (en) Suppression of proliferative responses and induction of tolerance by polymorphic class II MHC allopeptides
DK0969873T3 (en) Multiple carbohydrate-containing glycopeptide antigens, vaccine containing them, and use thereof
PT845998E (en) MEDICINES FOR IMMUNOTHERAPY CONTAINING ANTIBODIES THAT RECOGNIZE SPECIFICALLY THE MHCII ANTIGEN OF A PATIENT TO BE TREATED
EP0350690A3 (en) Neutralisation of the in vitro and in vivo toxic properties of tnf-alpha by monoclonal antibodies and by fragments derived therefrom
NO870476L (en) PROCEDURE FOR THE PREPARATION OF CROSS PROTECTIVE HUMAN MONOCLONAL ANTIBODY PREPARATIONS.
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
AR029624A1 (en) ANTIBODIES OR FRAGMENTS OF RECOMBINANT ANTI-IDIOTIPIC ANTIBODIES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
DE69007799D1 (en) PHARMACEUTICAL ANTIBODY-ANTIBODY COMPLEX CONTAINING COMPOSITIONS AND THEIR APPLICATIONS.
AU625171B2 (en) Specific excretion-secretion antigens of toxoplasma gondii, their expression products, processes for obtaining them and their diagnostic and prophylactic uses
DK0948319T3 (en) Encapsulated antibody-forming cells
ES2013321A6 (en) Monoclonal antibodies to Pseudomonas aeruginosaflagella
Gammelgaard et al. Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity
IT1171387B (en) STEROIDIC DERIVATIVES 20-ISONITRILE 17 (20) -UNSATURATED, PROCEDURE FOR THEIR PREPARATION, AND THEIR APPLICATION IN THE PREPARATION OF 17ALPHA-IDRCSSI-20-KETONIC STERIOIDS
DK102589A (en) ANTIGEN RECOGNIZED BY MCA 16-88
IT8320920A0 (en) DERIVATIVES OF CYCLOALKANES, PROCEDURE FOR THEIR PREPARATION AND COMPOSITIONS THAT CONTAIN THEM.
ES2084747T3 (en) EMULSION POLYMERS RELEASED FROM EMULSIONANTS IN PHARMACEUTICAL PREPARATIONS WITH DELAYED RELEASE OF THE ACTIVE SUBSTANCE, AND THEIR PREPARATION.
MX9202912A (en) NEW MONOCLONAL ANTIBODIES DIRECTED AGAINST THE VIRUSES OF HUMAN IMMUNOSUFFICIENCY AND THE PROCESS FOR ITS PREPARATION.